Candriam Equities L Biotechnology Class R USD Cap

Register to Unlock Ratings
Performance History30/04/2022
Growth of 1,000 (GBP) Advanced Graph
Candriam Equities L Biotechnology Class R USD Cap
Fund-5.030.816.5-1.0-6.4
+/-Cat3.010.6-9.58.010.1
+/-B’mrk-1.810.5-6.1-1.97.6
 
Key Stats
NAV
24/05/2022
 USD 202.50
Day Change -1.46%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU0942225912
Fund Size (Mil)
24/05/2022
 USD 1438.36
Share Class Size (Mil)
24/05/2022
 USD 137.06
Max Initial Charge 3.50%
Ongoing Charge
18/02/2022
  1.10%
Morningstar Research
Analyst Report

A growing team of highly qualified biotechnology experts led by one of the industry’s most seasoned investors in the field and a proven process give this fund an edge. The fund’s cheapest share classes receive a Morningstar Analyst Rating of...

Click here to read this analyst report on the underlying fund.
Morningstar Pillars
PeopleAbove Average
ParentAverage
ProcessAbove Average
Performance
Price
Investment Objective: Candriam Equities L Biotechnology Class R USD Cap
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund enables shareholders to invest in a portfolio of global equities in the biotechnology sector. The assets will be invested principally in the equities of companies operating in this sector.
Returns
Trailing Returns (GBP)24/05/2022
YTD-10.24
3 Years Annualised6.77
5 Years Annualised6.65
10 Years Annualised*15.43
12 Month Yield 0.00
Management
Manager Name
Start Date
Rudi Van den Eynde
06/04/2000
Servaas Michielssens
01/01/2019
Inception Date
08/11/2013
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Candriam Equities L Biotechnology Class R USD Cap31/03/2022
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.220.0095.22
Bond0.000.000.00
Property0.000.000.00
Cash4.780.004.78
Other0.000.000.00
Top 5 Regions%
United States81.00
Eurozone5.97
United Kingdom5.96
Europe - ex Euro3.57
Asia - Emerging1.44
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare6.47
Gilead Sciences IncHealthcareHealthcare5.62
Amgen IncHealthcareHealthcare5.49
Vertex Pharmaceuticals IncHealthcareHealthcare5.41
Illumina IncHealthcareHealthcare3.40
Candriam Equities L Biotechnology Class R USD Cap

Related

* This share class has performance data calculated prior to the inception date, 2013-11-08. This is based upon a simulated/extended track record, using the track record of Candriam Eqs L Biotech C USD Cap (ISIN: LU0108459040), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)